Menu
- syed.nasar@daneenbio.com
- +91-9321378847
We are now a Startup recognized by the Department for Promotion of Industry And Internal Trade, Ministry of Commerce and Industry, Government of India as well as Start up Bihar ,Government of Bihar,Department of Industries .
Cert No :1907
The Certificate of Recognition is attached. It can also be accessed using the below link:
DPIIT Certificate No: DIPP191049
OUR INSPIRATION
Khwaja Abdul Hamied FCS, FRIC (31 October 1898 – 23 June 1972) was an Indian industrial and pharmaceutical chemist who founded Cipla, India's oldest pharmaceutical company in 1935.
The great personality is our lots of inspiration.
WHO WE ARE
We are creating a new market under BLUE OCEAN Strategy by building worlds first vertically integrated platform for the CAR-T and STEM CELL THERAPY by the name DANEEN HEALTH HUB whereby we will provide treatment options to patients suffering from osteoarthritis and Blood cancer by “ first to market “ commercialized innovative CGT and Stem cell therapy products approved by CDSCO and DCGI in India at our partner clinics and hospitals through which patients can access and choose nearby Biotherapeutics centers where these biotherapies are available along with Doctors who will be treating the patients PAN INDIA and Globally starting with BIHAR .
Right now we are working on increasing the accessibility and affordibility below these two biotherapies in underserved regions of India .
1) StemOne :
Stempeucels® by Stempeutics PVT LTD is the first commercialized approved allogenic stem cell therapy product for treating CLI (Chronic Limb Ischemia ) and Knee OA (Osteoarthritis) in India commercialized and marketed by ALKEM LTD under brand StemOne.
Around 2000+ patients have been treated with this therapy since launch 2022 still there are 35 million active patients of osteoarthritis India alone and are going to be an increase by 40% of population affected in near future .
(b) NexCAR19 (Actalycabtagene autoleucel) :
IIT-B and Laurus Labs backed ImmunoACT Pvt Ltd have launched India’s first CAR-T cell therapy, NexCAR19 (Actalycabtagene autoleucel), for the treatment of r/r B-cell lymphomas and leukemia from the Central Drugs Standard Control Organization (CDSCO).
Currently, Indians, who sought CAR-T therapy, had to import the treatment at a substantial cost of Rs 3-4 crore per patient or go abroad but now NexCAR19 is available at less than 1/10 th of that cost per patient in India .
ImmunoACT aims to expand its CAR-T therapy platform and bring down treatment costs even further.
The company has the capacity to treat 500-750 patients per year, and they are looking to further scale up and reduce costs.
Around 500 + patients have been treated with this therapy all over India and is available at 86 hospitals across India till date .
OUR PRODUCTS
OUR SPECIALITY
With DANEEN BIOTHERAPEUTICS Health Specialty Pharmaceutical Distribution, you can:
•Access specialty products like ,Reference Listed Drugs, innovators, Comparators, Biologics, Biosimilars, Cell & Gene therapies .
•Receive emergency drugs quicker.
•Secure Vaccines, plasma, coagulation factors and other life-saving products .
•Make your first call to DANEEN BIOTHERAPEUTICS for unparalleled access to CRITICALLY needed life-SAVING drugs and specialty medications .
•DANEEN BIOTHERAPEUTICS ensures you have quick access to plasma, coagulation factors and other life-saving products when patients need them most.
TESTIMONIALS
Good service
Mylan India 
Thank you for your kind words and for the excellent service provided by Daneen Biotherapeutics. It has been a pleasure working with your team, and I truly appreciate the dedication, expertise, and support you bring to your clients.
I'd be happy to share a testimonial about my experience. Your commitment to delivering high-quality solutions has been invaluable, you and your team's professionalism and responsiveness have exceeded expectations. I look forward to continuing our partnership and benefiting from your outstanding service.
Incozen Therapeutics pvt ltd. 
Previous
Next
WHAT WE DO
The Named Patient Program (NPP) approval process in India is designed to provide patients with access to investigational drugs that are not yet approved by the Central Drugs Standard Control Organization (CDSCO).
NAMED PATIENT PROGRAME 
There is an URGENT need for a Comprehensive support and education to navigate the evolving biosimilars landscape and build broader understanding /consensus of the role biosimilars play in facilitating high quality, lower cost care in life threatening diseases
BIOSIMILARS 
Vaccines, allergenics, somatic cells, blood and blood components, recombinant therapeutic proteins and a wide variety of products which are isolated from natural sources including human, animals or microorganisms are categorised under Biologics.
BIOLOGICS 
Stempeucels® by Stempeutics India is the first commercialized approved allogenic stem cell therapy product for treating CLI (Chronic Limb Ischemia ) and Knee OA (Osteoarthritis) in India
STEM CELL APPROVED PRODUCT IN INDIA 
By replacing or making mutated cells inactive, cell and gene therapy can hit life-threatening diseases where it hurts the most . In this view, CGT has the potential to emerge as one of the futures biggest catalysts for providing innovative healthcare solutions and improving patient outcomes.
CELL & GENE THERAPY
DANEEN BIOTHERAPEUTICS aims to be the lifeline of global Clinical trials supply chains sourcing and procuring Biologics ,Biosimilars, CELL AND GENE THERAPY products ,Reference Listed Drugs, innovator drugs, Comparator Drugs, , for the pharmaceutical companies conducting clinical trials, CRO, and Sponsors.
RLD, INNOVATOR DRUGS,COMPARATOR DRUGS 
Previous
Next